COMMD6 (COMM domain-containing protein 6) is a member of the COMMD protein family, which consists of 10 evolutionarily conserved members (COMMD1-10) involved in diverse cellular processes, including copper homeostasis, transcriptional regulation, and intracellular signaling. COMMD6 has been implicated in modulating the nuclear factor-kappa B (NF-κB) signaling pathway, a key regulator of inflammation, immunity, and cell survival. Studies suggest that COMMD6 interacts with COMMD1 and other proteins to inhibit NF-κB activity, potentially influencing tumor progression, immune responses, and stress adaptation. Its role in copper metabolism remains less defined compared to other COMMD proteins like COMMD1. which is directly linked to Wilson’s disease.
Antibodies targeting COMMD6 are critical tools for investigating its expression, localization, and function in both physiological and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess COMMD6 protein levels in tissues or cultured cells. Research utilizing these antibodies has revealed altered COMMD6 expression in certain cancers, suggesting its potential as a biomarker or therapeutic target. For instance, downregulation of COMMD6 has been observed in hepatocellular carcinoma, correlating with enhanced NF-κB activation and tumor aggressiveness. Additionally, COMMD6 antibodies help elucidate its interactions with signaling molecules like IκBα or c-Rel, further clarifying its regulatory mechanisms. As interest grows in the COMMD family’s roles in disease, COMMD6 antibodies remain essential for advancing studies on cellular stress responses, oncogenesis, and immune modulation.